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An overt pro-inflammatory immune response is a key factor contributing to lethal
pneumococcal infection in an influenza pre-infected host and represents a potential
target for therapeutic intervention. However, there is a paucity of knowledge about the
level of contribution of individual cytokines. Based on the predictions of our previous
mathematical modeling approach, the potential benefit of IFN-γ- and/or IL-6-specific
antibody-mediated cytokine neutralization was explored in C57BL/6 mice infected with
the influenza A/PR/8/34 strain, which were subsequently infected with the Streptococcus
pneumoniae strain TIGR4 on day 7 post influenza. While single IL-6 neutralization had
no effect on respiratory bacterial clearance, single IFN-γ neutralization enhanced local
bacterial clearance in the lungs. Concomitant neutralization of IFN-γ and IL-6 significantly
reduced the degree of pneumonia as well as bacteremia compared to the control group,
indicating a positive effect for the host during secondary bacterial infection. The results of
our model-driven experimental study reveal that the predicted therapeutic value of IFN-γ
and IL-6 neutralization in secondary pneumococcal infection following influenza infection
is tightly dependent on the experimental protocol while at the same time paving the way
toward the development of effective immune therapies.
Keywords: co-infection, mathematical modeling, IFN-γ neutralization, IL-6 neutralization, Influenza Virus,
Streptococcus pneumoniae
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INTRODUCTION
Influenza A virus (IAV) infected individuals are predisposed to
severe secondary bacterial infections as observed in a substantial
number of fatal cases during influenza outbreaks (1). Such
complications due to bacterial super-infection substantially
contribute to morbidity and mortality and are frequently
caused by the gram-positive bacterium Streptococcus pneumoniae
(S. pn.) (2).
Influenza is a common respiratory pathogen that replicates
in alveolar epithelial cells of the respiratory tract. The anti-
viral immune response is characterized by high amounts
of type I interferons and a network of pro-inflammatory
cytokines. Consequentially, viral clearance is accomplished by
cytotoxic T cells and antibody responses (3). On the other
hand, S. pn. is an extracellular bacterial pathogen that can
cause a range of diseases, such as pneumonia, otitis media,
and meningitis, even though it is also a frequent colonizer
of the upper respiratory tract of asymptomatic children and
adults. In the lung, clearance of S. pn. largely depends on
alveolar macrophages (AM), neutrophils, and pro-inflammatory
cytokines (4). While for a long time it was believed that
breaches in the epithelial barriers caused by influenza infection
accounted for enhanced susceptibility to severe pneumococcal
infections, today we are aware that this synergism is more
complex. Multi-layered immune processes have been identified
that disturb efficient anti-bacterial host defense and allow severe
bacterial infections to establish in influenza-infected individuals.
Dysregulated cytokine responses during the underlying viral
infection as well as in response to the secondary bacterial
pathogen have been described and include both immune-
suppressive as well as exaggerated pro-inflammatory responses
(2, 5–7).
Co-infection experiments in mice provided the first
evidence that not only the disruption of the alveolar
epithelial barrier but also the suppression of AM phagocytic
function through interferon-γ (IFN-γ) plays an important
role for the fatal synergism between IAV and S. pn. (8, 9).
It is well-accepted that IFN-γ produced during the viral
infection downregulates the expression of the alveolar
macrophage receptor with collagenous structure (MARCO)
which in turn inhibits AM-mediated microbial clearance
and consequently leads to bacterial outgrowth and invasion
(8, 10–13). In humans, in addition to inflammatory
cytokines, bacterial loads in the co-infected lung were
positively associated with the level of the chemokine
CXCL-10 (14).
To enable targeted treatment of severe secondary bacterial
infections in influenza-infected individuals, a detailed
understanding of the underlying disease mechanisms is
critical. Mathematical approaches have been a valuable tool
in modeling the complex interactions and interdependencies
in influenza infection (15–19), pneumococcal infections
(20–22), co-infections (23–26), and the respective host
immune responses (27–34). Nevertheless, little research
has been done in the field of mathematical modeling
to better understand inflammatory responses and their
targeted neutralization during co-infections with IAV
and S. pn. (27).
In a data-driven mathematical modeling approach (27),
we have addressed the hierarchical contribution of different
pro-inflammatory cytokines on bacterial outgrowth in a
mouse model of secondary pneumococcal infection following
influenza infection and have identified IFN-γ and interleukin-
6 (IL-6) dynamics as strong and time-dependent factors for
bacterial invasion (27). Our model predicted that neutralization
of IFN-γ alone or in combination with IL-6, but not
neutralization of IL-6 alone, would restore bacterial clearance in
this setting.
The prophylactic and therapeutic strategies currently
available in the context of severe secondary bacterial infections
in influenza patients are limited and immune-modulation
of the dysregulated responses has emerged as a promising
approach (35). Therefore, we now explored the predictions
of our mathematical modeling approach in a model-driven
experimental approach in vivo. In order to test in silico
predictions and exploit the observed therapeutic potential
of cytokine-specific neutralizations, antibody-mediated
neutralizations of IFN-γ and/or IL-6 were performed in vivo
post primary influenza infection. In this animal model,
C57BL/6 mice were infected with S. pn. strain TIGR4 (103
or 106 CFU—colony-forming unit) on day 7 post sub-lethal
influenza infection (A/PR/8/34; 0.32 or 0.17 TCID50—Median
Tissue Culture Infectious Dose). The outcome of these
studies provides a rational framework for the development of
improved mathematical models and precise as well as effective
immune interventions.
RESULTS
IFN-γ Neutralization During Secondary
Pneumococcal Infection (106 CFU)
Following Influenza Infection (0.32 TCID50)
Leads to a Trend of Reduced Airway
Bacterial Burden
For local IFN-γ neutralization, influenza-infected mice were
treated with a neutralizing anti-IFN-γ antibody administered to
the respiratory tract together with the secondary bacterial
infection (Figure 1A), leading to significantly reduced
respiratory IFN-γ levels (Figure 1B). At the same time, there
was a trend toward a reduced bacterial burden in the lungs and
airways of the neutralizing antibody-treated group as compared
to the control-treated co-infected animals (Figure 1C). Of note,
a high load of bacteria was detected in the blood of only 60%
of the anti-IFN-γ antibody treated co-infected mice while 100%
of the control-treated co-infected mice showed a comparably
high degree of bacteremia (Figure 1C). In conclusion, even
though the neutralization of IFN-γ failed to restore bacterial
clearance and to significantly reduce bacterial outgrowth in
the respiratory tract of co-infected mice as predicted by the
mathematical model, we observed a strong trend for a potential
therapeutic benefit via reducing the bacterial burden in the
airways of co-infected animals.
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FIGURE 1 | Single IFN-γ neutralization during co-infection with 0.32 TCID50 IAV and 1 × 10
6 CFU S. pn. Mice were infected intranasally (i.n.) with 0.32 TCID50 IAV on
day 0. On day 7, mice were treated with anti-IFN-γ antibody and infected with 1 × 106 CFU S. pn. oropharyngeally (o.p.). The control group was infected likewise and
treated with an isotype IgG antibody. (A) Experimental setup. (B) IFN-γ protein levels in bronchoalveolar lavage (BAL) 24 h post antibody treatment and S. pn.
infection. (C) S. pn. bacterial counts in lung tissue, BAL and blood 24 h post antibody treatment and S. pn. infection. Data are shown for individual mice and lines
indicate the median/group. Controls in (C) are compiled from independent experiments. Statistical analysis was performed using the unpaired, one-sided
Mann-Whitney test [n.s., not significant (p > 0.05), **p < 0.01].
IL-6 Neutralization During Secondary
Pneumococcal Infection (106 CFU)
Following Influenza Infection (0.32 TCID50)
Leads to Significantly Reduced Bacteremia
Our previous mathematical model (27) predicted a synergistic
role for IL-6 in aggravating the detrimental effect of IFN-
γ in bacterial outgrowth following secondary pneumococcal
infection in IAV infected mice. However, neutralization of IL-
6 alone was not predicted to affect bacterial outgrowth or
clearance (27). In order to validate these predictions in vivo,
we also performed antibody-mediated neutralization of IL-
6 in co-infected mice. The co-infected mice were treated
with a neutralizing IL-6-specific antibody administered to the
respiratory tract together with the secondary pneumococcal
infection on day 7 post influenza infection (Figure 2A). The anti-
IL-6 antibody treatment led to significantly reduced IL-6 levels in
the respiratory tract compared to the control-treated co-infected
mice (Figure 2B). In contrast to the single IFN-γ neutralization
and in line with the predictions of our mathematical model,
single neutralization of IL-6 did not have a noticeable effect on the
respiratory bacterial burden (Figure 2C). However, surprisingly
there was a significant reduction in the systemic bacterial load
of the neutralizing antibody-treated mice as compared to the
control-treated co-infected mice (Figure 2C). Taken together,
while systemic dissemination was significantly less pronounced
following the neutralization of IL-6 alone, airway bacterial
outgrowth remained unaffected in line with the predictions of the
previous mathematical model (27).
Double Neutralization of IFN-γ and IL-6
During Co-infection Did Not Affect the
Bacterial Burden in the Airways Whereas
Bacteremia Was Significantly Reduced
In our previously published mathematical model, the
simultaneous neutralization of IFN-γ and IL-6 was highlighted
to enhance the positive effect of IFN-γ neutralization alone (27).
In order to test this prediction, mice were simultaneously treated
with the neutralizing antibodies for both IFN-γ and IL-6 through
administration to the respiratory tract during co-infection
(Figure 3A). While IFN-γ levels were significantly reduced in
the bronchoalveolar lavage (BAL) of the antibody-treated co-
infected mice, the reduction of IL-6 levels was substantial despite
it did not reach statistical significance (Figure 3B). Nevertheless,
as for the neutralization of IL-6 alone, the systemic bacterial
burden was significantly reduced following neutralization of both
IFN-γ and IL-6 as compared to the control-treated co-infected
mice (Figure 3C). However, the administration of anti-IL-6
antibody together with the anti-IFN-γ antibody did not reduce
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FIGURE 2 | Single IL-6 neutralization during co-infection with 0.32 TCID50 IAV and 1 × 10
6 CFU S. pn. Mice were infected intranasally (i.n.) with 0.32 TCID50 IAV on
day 0. On day 7, mice were treated with anti-IL-6 antibody and infected with 1 × 106 CFU S. pn. oropharyngeally (o.p.). The control group was infected likewise and
treated with an isotype IgG antibody. (A) Experimental setup. (B) IL-6 protein levels in bronchoalveolar lavage (BAL) 24 h post antibody treatment and S. pn. infection.
(C) S. pn. bacterial counts in lung tissue, BAL and blood 24 h post antibody treatment and S. pn. infection. Data are shown for individual mice and lines indicate the
median/group. Controls in (C) are compiled from independent experiments. Statistical analysis was performed using the unpaired, one-sided Mann-Whitney test
(*p < 0.05). CFU data are compiled from at least two independent experiments.
the bacterial burden in the respiratory tract of co-infected mice
(Figure 3C) and thereby did not recapitulate the predictions of
the mathematical model.
Single or Simultaneous Neutralization of
IFN-γ and IL-6 Did Not Have Beneficial
Effects in a Co-infection Model Employing
a Reduced Pneumococcal Dose (103 CFU)
In the utilized co-infection model pneumococcal outgrowth
in the respiratory tract is severe and reaches extremely high
bacterial counts as early as 18 h post the secondary infection.
Therefore, neutralization of IFN-γ and/or IL-6 was performed
in a low bacterial dose co-infection model (1 × 103 CFU). To
this end, mice were infected with 0.32 TCID50 IAV as described
above, co-infected with 1 × 103 CFU S. pn., and at the same
time treated through the administration of unchanged doses of
neutralizing antibodies specific for IFN-γ and/or IL-6 to the
respiratory tract (Figure 4A). As expected, in this co-infection
model, the lower dose of S. pn. was associated with a lower
grade of bacterial pneumonia (1 × 103-106 CFU) in contrast to
the high-grade pneumonia (1 × 107-108 CFU) observed post
co-infection with 1 × 106 CFU S. pn. (Figure 4B). Of note,
there was a clear and strong increase in the respiratory bacterial
burden in 1 × 103 CFU S. pn. co-infected as compared to
only S. pn. infected mice, which was however not statistically
significant. Also, no consistent dissemination of bacteria to the
circulation was detectable in the co-infected mice. In this model,
the administration of the neutralizing antibodies specific for IFN-
γ or IL-6 alone did not have any beneficial effects on bacterial
clearance in either case, as the respiratory bacterial burden was
unchanged between neutralizing antibody-treated and control-
treated co-infected mice (Figures 4B,C). Importantly, however,
a trend for a reduced bacterial burden was observed in the
airways post simultaneous neutralization of IFN-γ and IL-6 in
the co-infected mice as compared to control-treated co-infected
animals (Figure 4D). Nevertheless, taken together antibody-
mediated neutralization of IL-6 or IFN-γ as well as simultaneous
neutralization of both in a co-infection model utilizing a reduced
bacterial infectious dose also did not show the clear effects on
bacterial outgrowth and clearance predicted by our previously
mathematical model.
Repeated Neutralization of IFN-γ Alone or
in Combination With IL-6 Significantly
Reduces the Lung Bacterial Burden in
Secondary Pneumococcal Infection in a
Co-infection Model Based on Low
Infectious-Dose IAV Infection (0.17 TCID50)
In order to further characterize the effects of IFN-γ and/or
IL-6 neutralization on secondary pneumococcal infection
following IAV infection, the established co-infection model was
furthermore adjusted by reducing the infectious dose in the
underlying IAV infection. In order to compare the pathological
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FIGURE 3 | Double-neutralization of IFN-γ and IL-6 during co-infection with 0.32 TCID50 IAV and 1 × 10
6 CFU S. pn. Mice were infected intranasally (i.n.) with 0.32
TCID50 IAV on day 0. On day 7, mice were treated with anti-IFN-γ antibody together with anti-Il-6 antibody and infected with 1 × 10
6 CFU S. pn. oropharyngeally
(o.p.). The control group was infected likewise and treated with an isotype IgG antibody. (A) Experimental setup. (B) IFN-γ and Il-6 protein levels in bronchoalveolar
lavage (BAL) 24 h post antibody treatment and S. pn. infection. (C) S. pn. bacterial counts in lung tissue, BAL and blood 24 h post antibody treatment and S. pn.
infection. Data are shown for individual mice and lines indicate the median/group. Controls in (C) are compiled from independent experiments. Statistical analysis was
performed using the unpaired, one-sided Mann-Whitney test [n.s., not significant (p > 0.05), *p < 0.05, **p < 0.01]. Data are compiled from at least two
independent experiments.
features of the two different IAV infectious doses employed in our
study, pulmonary histopathology was performed on day 7 post
infection with 0.32 and 0.17 TCID50 IAV (Figure 5). Overview
images show a partial consolidation of the lung, predominantly
close to the hilus and affecting the parenchyma surrounding
the large bronchi (Figures 5A,B). In detail, major histological
hallmarks for IAV infection were observed for both infectious
doses, which were the accumulation of sloughed epithelial cells,
macrophages and degenerated neutrophils in the alveoli and
bronchiolar lumina as well as lymphocyte, macrophage and
neutrophil infiltration in the alveolar septae and the perivascular
as well as peribronchial interstitium (Figures 5C,D).
The inflammatory lesions were distributed multi-focally
or focally extensively and corresponded to the pattern of
a sub-acute broncho-interstitial pneumonia. Scorings of the
histopathological changes revealed little alteration between the
two viral doses (Figures 5E–G), whereas the percent of lung
tissue affected was on average smaller following infection with
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FIGURE 4 | Neutralization of IFN-γ and/or IL-6 during co-infection with 0.32 TCID50 IAV and 1 × 10
3 CFU S. pn. Mice were infected intranasally (i.n.) with 0.32
TCID50 IAV or left uninfected on day 0. On day 7, mice were treated with anti-IFN-γ antibody (B), anti-IL-6 antibody (C), or both (D) and infected with 1 × 10
3 CFU S.
pn. oropharyngeally (o.p.). The control groups were infected likewise and treated with an isotype IgG antibody. (A) Experimental setup. (B–D) S. pn. bacterial counts in
lung tissue, BAL and blood 24 h post antibody treatment and S. pn. infection. Data are shown for individual mice and lines indicate the median/group. Co-infected,
antibody-treated and co-infected control groups were compared using the unpaired, one-sided Mann-Whitney test [n.s., not significant (p > 0.05)].
0.17 as compared to 0.32 TCID50 IAV (Figure 5H). At the
same time, the lungs of PBS-treated mice did not show any
pathological findings (data not shown). A reduction of the overall
severity of the underlying IAV infection monitored as relative
body weight loss (data not shown) also enabled the repeated
administration of the neutralizing antibodies. Therefore, mice
were infected with 0.17 TCID50 IAV on day 0, neutralizing
antibodies specific for either IFN-γ alone or IFN-γ and IL-6
were intraperitoneally injected on day 5, followed by secondary
pneumococcal infection with 1 × 106 CFU of S. pn. and
the simultaneous administration of the respective neutralizing
antibodies to the respiratory tract on day 7 (Figure 6A). In this
model, neutralizations were only performed for IFN-γ alone or
in combination with IL-6 as these scenarios were predicted to
reduce bacterial outgrowth in the respiratory tract of co-infected
mice in the underlying mathematical model (27). At the same
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FIGURE 5 | Histopathological characterization of high and low dose IAV infection. WT C57BL/6J mice were intranasally infected with the A/PR8/34 H1N1 strain of
IAV. Images show a representative overview (A,B) and details (C,D); 400x) of the histopathological changes observed in the lungs on day 7 post infection with 0.32
(A,C) or 0.17 (B,D) TCID50 IAV following H&E staining. Bronchi (double crosses) contain few activated macrophages and the bronchiolar epithelium is attenuated and
partially sloughed into the lumen. Alveoli are filled by sloughed epithelial cells, macrophages (arrows), degenerated neutrophils (arrow heads), and cellular debris. The
alveolar septae and the perivascular and peribronchial interstitium are expanded by neutrophils, macrophages and lymphocytes (asterisks). Lymphocytic perivascular
infiltrations (E) and the number of lymphocytes (F) and neutrophils (G) in the alveoli were scored on a scale from 1 to 4 and the percent of the lung affected by the
infection (H) was evaluated and are shown for individual animals.
time, the previous experiments confirmed that neutralization
of IL-6 alone did not have a positive effect on the respiratory
bacterial burden in secondary pneumococcal infection following
influenza infection. While lowering the viral dose did not
lead to a substantial reduction in the airway levels of IFN-
γ and IL-6 detected 24 h following co-infection, neutralization
was exceptionally efficient following the administration of the
respective antibodies intraperitoneally on day 5 and to the
respiratory tract on day 7 post influenza infection (Figure 6B).
Of note, secondary pneumococcal infection with 1 × 106 CFU
S. pn. following infection with 0.17 TCID50 IAV led to a
significant bacterial outgrowth in the respiratory tract as well as
to significantly increased systemic dissemination as compared
to pneumococcal infection alone (Figure 6C). Importantly, in
this co-infection model, the neutralization of IFN-γ alone as
well as the simultaneous neutralization of IFN-γ and IL-6 led
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FIGURE 6 | Neutralization of IFN-γ and double-neutralization of IFN-γ and IL-6 during co-infection with 0.17 TCID50 IAV and 1 × 10
6 CFU S. pn. significantly reduced
the lung bacterial burden. Mice were infected intranasally (i.n.) with 0.17 TCID50 IAV or left uninfected on day 0. On day 5, mice were intraperitoneally (i.p.) injected
with anti-IFN-γ antibody alone or in combination with anti-IL-6 antibody. On day 7, mice were treated with anti-IFN-γ antibody alone or in combination with anti-IL-6
antibody and at the same time infected with 1 × 106 CFU S. p.n. oropharyngeally (o.p.). The control groups were infected likewise and treated with an isotype IgG
antibody. (A) Experimental setup. (B) IFN-γ and IL-6 protein levels in bronchoalveolar lavage (BAL) 24 h post antibody treatment and S. pn. infection. (C,D) S. pn.
bacterial counts in lung tissue, BAL and blood 24 h post antibody treatment and S. pn. infection. Data are shown for individual mice and lines indicate the
median/group. Co-infected, neutralizing antibody-treated were compared to co-infected, control-antibody-treated groups, and co-infected, control-antibody-treated
groups were compared to single-infected, control-antibody-treated groups using the unpaired, one-sided Mann-Whitney test [n.s. = not significant (p > 0.05),
*p < 0.05, **p < 0.01]. Data from co-infected mice are compiled from at least two independent experiments.
to a significant reduction of the lung bacterial load in co-
infected mice as compared to the control-treated co-infected
mice (Figures 6C,D). Although there was no complete bacterial
clearance, these observations clearly confirm the predictions
of the mathematical model regarding the beneficial potential
of neutralizing IFN-γ alone or in combination with IL-6
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for the restoration of disrupted anti-bacterial defense in the
respiratory tract during secondary pneumococcal infection
following influenza infection.
Neutralization of IFN-γ and IL-6 Alters the
Levels of Additional Cytokines in the
Respiratory Tract
Although in principle we confirmed the beneficial effect of
neutralizing IFN-γ and IL-6 for the host regarding the respiratory
bacterial burden in secondary pneumococcal infection following
influenza infection, there were substantial discrepancies between
the predictions of mathematical modeling and our experimental
results when attempting to validate these predictions in vivo. One
possible reason is the secondary effects of the neutralization of
single cytokines on the immunological network that have not
been considered in our modeling approach. In order to evaluate
the effect of neutralization of the targeted cytokines IFN-γ and
IL-6 on the network of pro-inflammatory mediators produced
in the airways in response to co-infection, the levels of TNF-
α, CCL-5, IL-1ß, GM-CSF, IL-10, IFN-α, IFN-ß, CXCL-10, IL-
12p70, CCL-2, and CXCL-1 were determined. Neutralization of
IFN-γ and/or IL-6 during co-infection with 0.31 TCID50 IAV
and 106 CFU S. pn. did not significantly change the airway levels
of these mediators (Supplementary Figure 1). However, in the
co-infection mouse model employing the reduced viral dose,
the neutralization of IFN-γ and IFN-γ together with IL-6 had
clear effects on the concentrations of TNF-α (Figure 7A), CCL-
5 (Figure 7B), IL-1ß (Figure 7C), and GM-CSF (Figure 7D).
A substantial reduction in the levels of these cytokines was
observed following single neutralization of IFN-γ, whereas the
simultaneous neutralization of IFN-γ and IL-6 in co-infected
mice led to significantly reduced levels. In contrast, IL-10, IFN-α,
IFN-ß, CXCL-10, IL-12p70, CCL-2, and CXCL-1 levels were also
not significantly affected by IFN-γ and IFN-γ/IL-6 neutralization
in co-infection with 0.17 TCID50 IAV and 1 × 10
6 CFU S.
pn. (Supplementary Figure 2). These observations clearly show
that next to its potential to positively affect bacterial clearance
the neutralization of specific cytokines during co-infection can
have multi-layered immune regulatory effects that also need
to be reflected by mathematical predictions to make them
more precise.
DISCUSSION
In our study, we tested predictions from an experimental data-
driven mathematical modeling approach in vivo. To this end
we assessed the effect of the neutralization of IFN-γ and/or
IL-6 during co-infection with IAV and S. pn. on the bacterial
load in the respiratory tract and the blood. Importantly, in
this modeling-driven experimental study, we initially employed
the established co-infection model that had been used before
to generate the data underlying the mathematical model. Here,
levels of IFN-γ and IL-6 peaked on day 7 following IAV infection
(Supplementary Figure 3) and therefore this time-point has
been chosen to evaluate the effects of their neutralization.
However, single respiratory tract IFN-γ neutralization on day
7 post IAV infection, performed concomitant with the bacterial
infection, largely failed to recapitulate the mathematical model
predictions (27). Interestingly, however, treatment with the IL-6
neutralizing antibody alone as well as in combination with the
IFN-γ neutralizing antibody led to significantly reduced systemic
bacterial burdens in co-infected mice. Strikingly, simultaneous
neutralization of IFN-γ and IL-6 was less efficient with respect
to reducing IL-6 levels than neutralization of IL-6 alone.
Most likely, this observation was due to secondary effects of
the additional neutralization of IFN-γ on IL-6 production or
pathology, which in turn lead to altered inflammatory conditions
and responses, Ultimately, future studies will be needed to clarify
a possible distinct role for IL-6 in secondary pneumococcal
infection following IAV infection and here especially in bacterial
dissemination from the respiratory tract.
Based on our findings in the original co-infection setting, two
time-points of neutralization, i.e., one intraperitoneal injection
on day 5 and one administration via the respiratory route
on day 7 post IAV infection, were tested in an adjusted
infection model. Even though neutralization of IFN-γ has been
reported to have only minimal effects on the course of IAV
infection (8), in our co-infection models using 0.32 TCID50
IAV it adversely affected the general condition of the animals
as reflected by overt body weight loss (data not shown).
Therefore, the repetitive neutralizations were performed in
a co-infection model utilizing a reduced viral load. Primary
infection with a reduced viral dose of 0.17 TCID50 IAV
led to similar histopathological changes and, importantly, still
significantly increased susceptibility to secondary pneumococcal
infection including systemic dissemination on day 7 post
influenza infection.
Consistent with previous co-infection experiments by Smith
et al. (23) our results therefore show that the initial IAV infectious
dose does not strongly affect the secondary bacterial outgrowth
and invasion. In line with this, respiratory IFN-γ and IL-6
levels were similarly high or even higher in pneumococcal co-
infection following infection with 0.17 TCID50 IAV. Importantly,
in this experimental system of secondary pneumococcal infection
following infection with a reduced dose of IAV as well as repeated
cytokine neutralization, the degree of bacteremia, as well as the
grade of pneumonia, was significantly reduced as compared to
the respective control group, indicating a positive effect on the
response to secondary bacterial infection. Future studies will have
to unravel in detail whether the lower viral dose, the higher doses
of the neutralizing antibodies, their repeated administration
via the intraperitoneal as well as the respiratory route or the
effects on other cytokines are key to the significant beneficial
effects observed. On the one hand, while both viral doses
significantly predisposed for secondary pneumococcal outgrowth
and dissemination, the extent of lung tissue affected by the viral
infection itself was dose-dependent, which consequently may
have influenced the efficacy of neutralizations scenarios. On the
other hand, together with reducing the viral dose also the doses
of the neutralizing antibodies were increased and led to a more
efficient neutralization of IL-6 in the combinatorial neutralization
of IFN-γ and IL-6. At the same time, these higher neutralizing
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FIGURE 7 | Double-neutralization of IFN-γ and IL-6 during co-infection with 0.17 TCID50 IAV and 1 × 10
6 CFU S. pn. significantly affects TNF-α, CCL-5, Il-1ß, and
GM-CSF protein levels in BAL. Mice were infected intranasally (i.n.) with 0.17 TCID50 IAV on day 0. On day 5, mice were intraperitoneally (i.p.) injected with anti-IFN-γ
antibody alone or in combination with anti-Il-6 antibody. On day 7, mice were treated with anti-IFN-γ antibody alone or in combination with anti-IL-6 antibody
oropharyngeally (o.p.) and at the same time infected with 1 × 106 CFU S. pn. o.p. The control group was treated with an isotype IgG antibody and infected likewise.
(A–D) Protein levels of TNF-α, CCL-5, Il-1ß, and GM-CSF in bronchoalveolar lavage (BAL) 24 h post o.p. antibody treatment and S. pn. infection. Data are shown for
individual animals indicating the median/group and are compiled from two independent experiments. Neutralizing antibody-treated groups were compared to the
control antibody-treated group using the unpaired Kruskal-Wallis test with Dunn’s test for multiple comparisons (*p < 0.05, **p < 0.01).
antibody doses were administered on days 5 and 7 post IAV
infection as compared to a single administration in co-infections
following 0.32 TCID50 IAV. Of note, both intraperitoneal, as
well as respiratory tract-directed administration, have been
described for the administration of antibody-treatments in
pulmonary studies (8, 36). For multiple administrations of the
higher antibody doses, the intraperitoneal injection was chosen
to avoid additional anesthesia. Taken together, our results in
principle confirm the predictions of our mathematical model,
i.e., the potential of neutralizing IFN-γ alone and in combination
with IL-6 for restoring anti-bacterial host defense in secondary
pneumococcal infection following IAV infection. At the same
time, the clear synergistic effect for simultaneously neutralizing
IFN-γ and IL-6, as predicted by the mathematical model, was not
observed in vivo as additional neutralization of IL-6 abolished
the positive trend observed for IFN-γ neutralization following
co-infection with 0.32 TCID50 IAV and 1 × 10
6 CFU S.
pn. Ultimately, the detailed inter-dependencies will have to be
addressed together with the question, how the observed benefits
can be extended and whether they can be translated to decreased
morbidity andmortality in secondary bacterial infection, possibly
also in combination with antibiotic treatment (37).
Counterintuitively, a reduction in the bacterial dose had
little influence on the effect of the cytokine neutralization.
By a factor of 1000 reduction in bacterial dose was tested to
evaluate if the positive effect of double neutralization predicted
by the mathematical model could be achieved. However, the
bacterial load remained unchanged between the neutralizing
antibody-treated and the control-treated co-infected groups
(Figure 4). While the neutralization of IFN-γ and IL-6 alone led
to marginally increased bacterial loads in the respiratory tract of
co-infected mice, their simultaneous neutralization led to a small
trend for decreased respiratory bacterial burdens. Ultimately,
there was however not even a significant increase in the bacterial
burden following secondary pneumococcal infection at a dose of
1 × 103 CFU on day 7 post IAV infection with 0.32 TCID50,
suggesting a threshold bacterial dose is necessary to establish
severe secondary infection including systemic dissemination.
Of note, this significant synergism was clearly observed in co-
infection with 1 × 106 CFU S.pn. on day 7 post infection with
0.17 TCID50 IAV.
Our original mathematical model (27) predicted the
restoration of bacterial clearance through the neutralization of
IFN-γ alone and in combination with IL-6 during co-infection
with 0.32 TCID50 IAV and 1 × 10
6 CFU S. pn. While we
observed trends as well as significant decreases in respiratory
bacterial loads and systemic dissemination in the different
experimental approaches of our study, there is no consistent
evidence of restored bacterial clearance. These results were
therefore behind the predictions and expectations from the
mathematical modeling and the in silico cytokine neutralizations.
In particular, the mathematical models (27) did not consider
Frontiers in Immunology | www.frontiersin.org 10 August 2019 | Volume 10 | Article 1864
Sharma-Chawla et al. Immunotherapy During Co-infection Post Influenza
that neutralization protocols would have a delay to promote
innate immune cells to recover their phagocytosis efficiency.
Furthermore, we show that simultaneous neutralization of
IFN-γ and IL-6 can have clear and significant effects on levels of
other pro-inflammatory mediators, thereby profoundly altering
the local inflammatory milieu and immune network, possibly
also affecting viral clearance. As an example, neutralization of
IFN-γ and IL-6 during co-infection with 0.17 TCID50 IAV and
1 × 106 CFU S. pn. significantly decreased GM-CSF levels. Its
overexpression in turn has been shown to prevent mortality
and modulate macrophage polarization in IAV infection in
mice (38) and inhaled GM-CSF therapy has been shown to have
benefits in patients with pneumonia-associated acute respiratory
distress syndrome (39). Such effects were however not part of
the underlying mathematical model, whereas they most likely
do have direct or indirect effects on the mechanisms of anti-
bacterial defense in co-infection. Furthermore, these findings
demonstrate potentially harmful effects for neutralizing single
or multiple cytokines that need to be taken into account. While
mice deficient in IFN-γ signaling have been shown to effectively
respond to IAV infection (8), a crucial role for IL-6 has been
described (40, 41). Of note, multiple time-point neutralization
of IFN-γ following IAV infection with 0.32 TCID50 increased
morbidity in our system (data not shown). Therefore, exact
knowledge of the balance between beneficial and detrimental
cytokine effects during IAV and co-infection will be essential for
further evaluation of the therapeutic potential of neutralizations
and likewise for the development of precise models. Of note,
while in co-infections the detrimental effects of IFN-γ have been
described (8), this is less clear for IL-6 but suggested by the
positive effect of IL-6 neutralization on systemic dissemination.
Our findings have shed light into themultitude of inter-related
immune-regulatory pathways in action in a co-infection setting,
drawing a more complex picture for mathematical modeling.
Even though the levels of IFN-γ following neutralization (∼500-
fold reduction reached 24 h post antibody treatment) were
consistent during the time of co-infection (Figure 8A), refined
mathematical simulations in Figure 8B show a strong time
dependency to recover necessary levels of phagocytosis to avoid
a bacterial invasion as depicted in Figure 8C. However, with
the data available from our different approaches for cytokine
neutralization and co-infection, these modeling results can only
be taken in a qualitative form.
Note that also our neutralization protocols may have different
limitations to differences in mouse strains. A very recent study by
Metzger’s group (12) presented data that BALB/c mice exhibited
a strong IFN-γ dependent reduction in AM numbers post
influenza infection. On the other hand, AM levels in C57BL/6
mice were maintained throughout the course of influenza
infection, however, cells displayed an altered phenotype. These
mouse strain-dependent differences were observed regardless
of viral strains or whether the infection was performed with
low or high doses. However, the mechanisms responsible for
differential AM responses in BALB/c and C57BL/6 mice are
unknown (12). The most conceivable theory is that immune
responses in C57BL/6 mice are preferentially skewed toward the
Th1 and M1 lineage, whereas BALB/c mice are believed to be
prone to develop Th2- and M2-dominated responses (42, 43).
Ultimately, AM depletion was rescued in IFN-γ−/− BALB/c
mice improving bacterial clearance and disease outcome in this
mouse strain (8, 12). Thus, these findings together with our
study underline the multitude of factors, including skews in the
host immune response, to be considered for designing reliable
mathematical models and for designing effective and precise
therapeutic approaches.
Even though the previous in silico predictions of our
mathematical model were not fully met in vivo, the results of this
model-driven experimental study emphasize the potential and at
the same time illustrate the limitations of modeling approaches,
thereby significantly contributing to the current knowledge and
building a basis for future approaches translating improved
mathematical models into potential therapies.
METHODS
Mice
Nine to eleven weeks old C57BL/6JOlaHsd female mice were
purchased from Envigo (formerly known as Harlan Laboratories,
Venray, Netherlands) and were housed in a specific pathogen-
free environment according to the guidelines of the regional
animal care committee. All the experiments were approved
and conducted in accordance to the guidelines set by the local
animal ethical bodies for the Helmholtz Centre for Infection
Research (Niedersächsisches Landesamt für Verbraucherschutz
und Lebensmittelsicherheit, animal permit code: 16/2319). Mice
were age-matched for all the experiments. All mice were closely
monitored and scored for weight loss, posture, pilo-erection,
respiration, eye discharge, redness of the eye conjunctiva and
response to stimulus. Animals with severe symptoms were
euthanized and the infection was considered as lethal.
Bacterial and Viral Preparations
The pneumococcal serotype 4 strain TIGR4 (T4; ATCC BAA-
334) was used. Bacteria were grown to the mid-logarithmic
growth phase (optical density of 0.35 at 620 nm) in freshly
prepared pre-warmed THY medium (THB Sigma-Aldrich,
Germany and yeast extract, Roth, Germany) at 37◦C in a water
bath and were harvested by adding 10% v/v glycerol (Roth,
Germany) before storage at −70◦C. For mouse infections, the
frozen stocks were thawed, centrifuged, washed once in 1ml of
phosphate-buffered saline (PBS, Gibco, UK) and subsequently
pelleted before diluting to the desired concentration. The
challenge dose was confirmed for each infection by plating 10-
fold serial dilutions on blood agar plates (BD Diagnostic Systems,
Columbia Agar with 5% sheep blood, Germany) and overnight
incubation at 37◦C and 5% CO2.
For IAV infection, the viral strain PR8/A/34 had been
previously produced in adherent Madin-Darby canine kidney
(MDCK) cells (44). The 50% tissue culture infectious dose
(TCID50) was determined by incubating 10-fold serial
dilutions of the viral stock on MDCK cells in Dulbecco’s
modified eagle medium (DMEM; Life Technologies, Germany)
supplemented with 0.0002% trypsin (Sigma-Aldrich, Germany)
and 1% penicillin/streptomycin (ThermoFisher, USA) for 5
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FIGURE 8 | Computational simulations of single or double-neutralization of IFN-γ and IL-6 during co-infection with 0.32 TCID50 IAV and 1 × 10
6 CFU S. pn. (A) The
blue line represents the IFN-γ kinetics during co-infection (control) and the red line shows the IFN-γ concentration kinetics based on the neutralization protocol
(∼500-fold reduction respect co-infection). Note that the continuous blue line is built with a piecewise linear function of the experimental data points. The red line is
based on the control case but adjusted to pass by the time point of anti-IFN- γ experiments. (B) Bacterial clearance function φ (Equation 5) during neutralization
protocol of IFN-γ. (C) The blue line represents the bacterial load in the lungs during co-infection (control) while the red line displays the neutralization protocol. The
different color dots represent the data of different neutralization protocols.
days followed by addition of 0.5% chicken red blood cells
(Fiebig Naehrstofftechnik, Germany) to the culture medium.
Agglutination of the red blood cells was documented and the
TCID50 was calculated using the endpoint calculation by Reed
and Muench (45).
Mouse Infection Models
Prior to infection, all mice were weighed and anesthetized
through intraperitoneal administration of a ketamine (WdT,
Germany; 10 g/100ml) and xylazine solution (Bayer, Germany;
2 g/100ml) at a dose of 0.1 ml/10 g mouse body weight.
S. pn. was administered to the respiratory tract through
oropharyngeal instillation (46). Mice were placed on their back
on an intubation slope, the mouth was held open and the tongue
gently placed to the side of the mouth using flat head forceps. A
cold light lamp with a flexible light guide was used to illuminate
the anterior pharynx and the challenge dose of 1× 106 or 1× 103
colony forming units (CFU) S. pn. in 25 µl PBS was instilled into
the laryngopharynx using a flexible gel loading pipet tip (Corning
Inc., USA). After application of the inoculum, the nares were
manually blocked for 5 s to ensure breathing through the mouth
and aspiration of the inoculum into the trachea. Control groups
received 25µl of sterile PBS. For the intranasal instillation of IAV,
mice were held upright with the head slightly tilted back and the
inoculum was administered dropwise to the nares in a volume of
25 µl sterile PBS.
Antibody-Mediated Cytokine Neutralization
Protocols
Antibody-mediated neutralization of IFN-γ and IL-6 was
performed using the rat anti-mouse IFN-γ antibody clone AN-
18 (FPLC-purified from hybridoma) and the rat anti-mouse
IL-6 antibody clone MP5-20F3 (Bio X Cell), respectively. A
rat control IgG1 isotype (TNP6A7; Bio X Cell) was used as
control antibody. All antibodies were sterile, azide-free and low-
endotoxin, suitable for in vivo administration. Mice infected
with 0.32 TCID50 IAV were treated with 200 µg anti-IFN-γ
and/or 100µg anti-IL-6 antibody oropharyngeally on day 7 post-
IAV infection together with the secondary bacterial infection to
deliver the neutralizing antibodies to the respiratory tract. Mice
infected with 0.17 TCID50 IAV were treated intraperitoneally
with 400 µg anti-IFN-γ antibody alone or in combination with
200 µg anti-IL-6 antibody on day 5 post influenza infection. On
day 7 post influenza infection, these mice were oropharyngeally
treated with 200µg anti-IFN-γ antibody alone or in combination
with 100 µg anti-IL-6 antibody together with the secondary
bacterial infection.
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Assessment of the Bacterial Burden
Animals were sacrificed using CO2 inhalation. BAL was
obtained by flushing the lungs once with 1ml PBS via the
trachea using a 22G indwelling cannula (Braun, Germany).
Following perfusion, the lungs were excised, and the tissue
was mechanically homogenized in 1ml PBS by passing
through a 70µm filter (Corning Inc., USA). Cardiac
blood was collected and diluted in PBS. Bacterial CFU
were determined by plating serial dilutions of BAL, post-
lavage lung homogenates and blood on blood agar plates.
The plates were incubated for 16–18 h at 37◦C and 5%
CO2, CFU were manually counted and the CFU per ml
were calculated.
Detection of Cytokines in BAL
An enzyme-linked immunosorbent assay (ELISA) was used
to determine the protein concentrations of IL-6. A 96-well
Nunc ELISA plate (F96 Maxisorp Nunc-immuno plate, Thermo
Scientific) was coated with 0.5µg/ml of the capture antibody
MP5-20F3 (Bio X Cell). Washing was performed with the
Power Washer (Tecan). To prevent unspecific binding, 200 µl
of blocking buffer were added and the plate was incubated on
a shaker for 1 h at room temperature. Subsequently, 50 µl of
sample were added and incubated for 2 h at room temperature
on a shaker. An IL-6 protein standard (recombinant mouse
IL-6, BioLegend) was used at concentrations of 500, 250, 125,
61.5, 32.3, 15.6, and 7.6 pg/ml. After the incubation, the
plate was washed and incubated with 50 µl of the detection
antibody (1.25µg/ml; MP532C11, BD Pharmingen) for 1 h.
This incubation was followed by washing and adding 50 µl
of 1:2000 diluted Streptavidin-horse radish peroxidase (BD
Pharmingen). The plate was incubated for 30–45min in the dark
and washed before adding 50 µl of TMB substrate (BIOZOL).
Following the addition of 50 µl ELISA stop solution (15min) the
absorption at 450 nm was read by using a photometer (TECAN
Sunrise). The background absorption was read at 570 nm as
the reference.
For the detection of IFN-γ protein levels through
ELISA, a similar protocol was followed. The capture
antibody (AN-18; FPLC-purified from hybridoma) was
used at a concentration of 2.7µg/ml, the standard was the
recombinant mouse IFN-γ (BioLegend) and the detection
antibody (R4-6A2; FPLC-purified from hybridoma) was
diluted to a working concentration of 0.6µg/ml. For the
simultaneous detection of IL-6, IFN-γ, TNF-α, CCL-5, IL-
1ß, GM-CSF, IL-10, IFN-α, IFN-ß, CXCL-10, IL-12p70,
CCL-2, and CXCL-1 in BAL samples a flow-cytometry
based multiplex detection assay (LegendPlex mouse anti-
virus response panel, BioLegend) was used according to the
manufacturer’s recommendations.
Histopathological Analysis
Lungs were fixed in 4% formalin and routinely embedded
in paraffin. Sections were cut 5µm thick, dewaxed,
and stained with hematoxylin and eosin (H&E). A
blinded histopathological evaluation was performed by a
veterinary pathologist certified by the European College of
Veterinary Pathologists.
Mathematical Modeling
To understand the limitation of previous predictions (27), we
employ as a starting point our previous mathematical work











where r (1.13 h−1) is the bacterial proliferation rate with
a maximum carrying capacity KB (2.3 × 10
8 CFU/ml).
Phagocytosis of the bacteria is considered by the multiplicative
term cbfx, where cb (1.28 h
−1) is the constant phagocytosis
rate. The term fx is the mathematical function which served
to test different hypotheses. The biological meaning of fxis
the bacterial clearance inhibition provided by the inflammation
to alveolar macrophages (AMs). In this work, we use here
the model M7 from previous mathematical work (27), which
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where A1 = 4.05 x 10
7 and A2 = 5.46 x 10
4. Note
that the terms for IL-6(t) and IFN-γ(t) are not modeled
mechanistically but as piecewise linear functions from the
experimental data (27), which is considered as an input to the
Equation (2).
Our previous modeling work assumed that pro-inflammatory
cytokines directly affect bacterial clearance. However, there
may be a time interval where immune cells responsible
(e.g., macrophages) for bacterial clearance return to levels
that sufficiently clear the bacterial infection. Therefore,
the importance to model kinetically the dynamics of
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where M(t) represents the alveolar macrophages (AM) cells
that are mainly responsible for bacterial clearance (47). The
rationale of Equation (4) is based on previous modeling works
(20) to represent the dynamics of alveolar macrophages that
is considered as the main component of the innate immune
system to encounter the bacterial infection when entering
the airway. It is assumed a constant influx of macrophages
with the term SM and a death rate dM . Parameter values are
sM = M(0)dM , and dM = 1/25 h
−1 as reported by Smith
et al. (20).
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While in the naive conditions (free infection) it is assumed
not any changes of AM, that is M(0) = 1, the number of active
macrophages is decreased during influenza infection as reported
in previous experimental studies (10). In a similar direction
to previous modeling (24), we consider a simple monotone
increasing function with respect to AM dynamics. Note that
other more complex terms could have been used for ∅(t),
however, due to the limitations in the number of data points
during neutralizations we consider the simple monotone term.
Smith et al. (24) derived a critical non-linear threshold which
dictates the bacterial invasion during co-infection, which is
about 0.8. As the experimental protocols are consistent to those
presented here, it is reasonable to assume that the parameter θ
for starting our simulations at the day of co-infection should be
<0.2. Thus, we consider M(tc) = 0.1, where tc is the moment
of co-infection.
Statistical Analysis
Graph Pad Prism 5.0 (Graph Pad software, La Jolla, USA) was
used to perform the indicated statistical tests.
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